Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Appointed director
Oyster Point Pharma, Inc. (OYST) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/14/2023 SC 13G/A Paradigm Biocapital Advisors LP reports a 0% stake in Oyster Point Pharma, Inc.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/13/2023 15-12G Form 15-12G - Securities registration termination [Section 12(g)]:
01/13/2023 8-K/A Resignation/termination of a director
01/13/2023 SC 13D/A Versant Venture Capital VI, L.P. reports a 0% stake in OYSTER POINT PHARMA, INC.
01/09/2023 SC 13D/A New Enterprise Associates 14, L.P. has filed a Schedule 13D for Oyster Point Pharma, Inc.
01/06/2023 EFFECT Form EFFECT - Notice of Effectiveness:
01/05/2023 SC 13D/A InvOpps IV US, L.P. reports a 0% stake in Oyster Point Pharma, Inc.
01/03/2023 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
01/03/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
01/03/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
01/03/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
01/03/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
01/03/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
01/03/2023 8-K Resignation/termination of a director
Docs: "Second Amended and Restated Certificate of Incorporation of Oyster Point Pharma, Inc.",
"Second Amended and Restated Bylaws of Oyster Point Pharma, Inc."
01/03/2023 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
01/03/2023 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
12/23/2022 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
12/22/2022 SC 14D9 Form SC 14D9 - Solicitation, recommendation statements:
12/20/2022 SC 13D/A InvOpps IV US, L.P. reports a 10.3% stake in Oyster Point Pharma, Inc.
12/09/2022 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
12/09/2022 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
12/01/2022 SC 14D9 Form SC 14D9 - Solicitation, recommendation statements:
12/01/2022 SC TO-T Form SC TO-T - Tender offer statement by Third Party:
11/21/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
11/16/2022 SC14D9C Form SC14D9C - Written communication relating to third party tender offer:
11/14/2022 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party:
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 8-K Quarterly results
11/08/2022 SC14D9C Form SC14D9C - Written communication relating to third party tender offer:
11/08/2022 8-K Quarterly results
11/08/2022 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party:
11/07/2022 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party:
11/07/2022 SC14D9C Form SC14D9C - Written communication relating to third party tender offer:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy